Drug Trial Radar · NCT06780462
Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome
Last checked: Nov 20, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
134
Planned (sponsor's estimate)
Start
Jun 24, 2025
Primary completion
Dec 24, 2027
Study completion Jun 24, 2028
Sponsor
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In patients with Behçet's syndrome (BS), deep venous thrombosis (DVT) is thought to result from inflammation of the vessel wall rather than hyper coagulability. Post Thrombotic Syndrome (PTS) is frequent especially with recurrent episodes of deep vein thrombosis and may result in leg ulcers that are very difficult to treat. Vascular involvement is a major cause of morbidity and mortality among BS patients. However, one of the most controversial issues regarding the management of BS is whether DVT should be treated with anticoagulants. Moreover, use of anticoagulants exposes patients to serious bleeding, especially in those who presents simultaneous arterial aneurysms. However, many physicians are still using anticoagulants. This is the first prospective, randomized study assessing benefits of corticosteroids associated with anticoagulant compared to that of corticosteroids alone in DVT in BS patients. It will validate or not the use of anticoagulants in those situations. It will allow a direct comparison of the safety profile of those two schemes of treatment.
Conditions
- Behcet Syndrome
Interventions
Corticosteroids + RivaroxabanDrug
Corticosteroids according to the schedule of reduction of prednisone (or equivalent prednisone dose only if prednisone is out of stock in the market) and Rivaroxaban
Corticosteroids aloneDrug
Corticosteroids according to the schedule of reduction of prednisone (or equivalent prednisone dose only if prednisone is out of stock in the market)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of successTime frame: At 6 months
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
CHU BORDEAUX Hôpital Saint-André
Bordeaux, France · Recruiting
Ambroise Paré hospital AP-HP
Boulogne-Billancourt, France · Recruiting
CHU Caen
Caen, France · Recruiting
Hopital Henri Mondor AP-HP
Créteil, France · Recruiting
Chu de Grenoble
Grenoble, France · Recruiting
Hôpital Bicêtre
Le Kremlin-Bicêtre, France · Recruiting
Hcl, Hopital de La Croix Rousse
Lyon, France · Recruiting
Centre Hospitalier de Melun
Melun, France · Recruiting
CHRU DE Nancy Hôpitaux de Brabois
Nancy, France · Recruiting
Hôpital Hôtel-Dieu
Nantes, France · Recruiting
Hopital Européen Georges Pompidou AP-HP
Paris, France · Recruiting
Hôpital Lariboisière AP-HP
Paris, France · Recruiting
Hôpital Saint Antoine AP-HP
Paris, France · Recruiting
Hôpital Tenon AP-HP
Paris, France · Recruiting
La Pitié Salpetriere hospital
Paris, France · Recruiting
CHU Bordeaux- GHU SUD hôpital Haut-Lévêque
Pessac, France · Recruiting
CHU DE ROUEN, Hôpital CHARLES NICOLLE
Rouen, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.